NASDAQ:MNPR • US61023L2079
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MONOPAR THERAPEUTICS INC (MNPR).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-30 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-02-23 | BTIG | Reiterate | Buy -> Buy |
| 2026-02-02 | BTIG | Reiterate | Buy -> Buy |
| 2026-01-29 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-01-14 | BTIG | Reiterate | Buy -> Buy |
| 2026-01-09 | Morgan Stanley | Initiate | Overweight |
| 2025-11-14 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2025-11-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-10 | Leerink Partners | Initiate | Outperform |
| 2025-11-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-13 | Barclays | Initiate | Overweight |
| 2025-10-06 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2025-10-02 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-25 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-25 | BTIG | Maintains | Buy -> Buy |
| 2025-09-25 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-09-23 | Lake Street | Initiate | Buy |
| 2025-09-16 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-15 | BTIG | Reiterate | Buy -> Buy |
| 2025-09-09 | BTIG | Initiate | Buy |
| 2025-09-03 | Oppenheimer | Initiate | Outperform |
| 2025-09-03 | Raymond James | Initiate | Strong Buy |
| 2025-08-27 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-08-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 248.08% | N/A 57.92% | N/A 64.40% | N/A 47.98% | N/A 46.62% | N/A 32.74% | |||||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A -171.48% | N/A 15.77% | N/A 122.22% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -1.19M | -16.6M -1,294.96% | -3.33M 79.94% | -4.32M -29.73% | -6.51M -50.69% | -9.13M -40.25% | -10.54M -15.44% | -8.831M 16.21% | -16.162M -83.01% | -16.704M -3.36% | N/A -117.96% | N/A 7.25% | N/A 55.74% | N/A 258.98% | N/A 257.05% | N/A 127.50% | N/A 57.21% | N/A 37.79% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | -2.95 -48.32% | -3.70 -25.42% | -4.15 -12.16% | -3.05 26.51% | -4.12 -35.08% | -1.85 55.10% | N/A -109.40% | N/A -7.73% | N/A 46.31% | N/A 92.94% | N/A 2,046.77% | N/A 247.31% | N/A 61.55% | N/A 41.94% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.87 -128.04% | -0.81 -130.32% | -0.99 -106.34% | -1.24 -93.80% | -1.03 -18.89% | -1.04 -29.06% | -4.98 -402.57% | -0.87 30.10% |
| Revenue Q2Q % growth | N/A | N/A | 1.836M | 11.424M | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.353M -159.27% | -8.7M -168.98% | -10.09M -146.50% | -11.052M -79.55% | N/A | N/A | N/A | N/A |
All data in USD
20 analysts have analysed MNPR and the average price target is 115.04 USD. This implies a price increase of 104.63% is expected in the next year compared to the current price of 56.22.
MONOPAR THERAPEUTICS INC (MNPR) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of MONOPAR THERAPEUTICS INC (MNPR) is -0.87 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering MONOPAR THERAPEUTICS INC (MNPR) is 20.